Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Nov 2014
Scoring systems for 6-month mortality in critically ill cirrhotic patients: a prospective analysis of chronic liver failure - sequential organ failure assessment score (CLIF-SOFA).
Cirrhotic patients admitted to intensive care units (ICUs) have high mortality rates. The Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) score, a modified Sequential Organ Failure Assessment (SOFA) score, is a newly developed scoring system exclusively for patients with end-stage liver disease. ⋯ Both CLIF-SOFA and APACHE III scores are excellent prognosis evaluation tools for critically ill cirrhotic patients.
-
Aliment. Pharmacol. Ther. · Oct 2014
ReviewSystematic review: the effect of prunes on gastrointestinal function.
Prunes (dried plums) are high in fibre and are perceived to promote healthy gastrointestinal (GI) function. ⋯ In constipation, prunes appear superior to psyllium for improving stool frequency and consistency, however, the evidence for other outcomes and the effects in non-constipated subjects is weak. Although prunes may be a promising intervention for the management of constipation and increasing stool weight, this needs to be confirmed by further rigorous research.
-
Aliment. Pharmacol. Ther. · Oct 2014
Review Meta AnalysisSystematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer.
Major adjuvant therapies for biliary tract cancer (BTC) include fluorouracil, gemcitabine and chemoradiation (CRT), but the optimum regimen remains inconclusive. ⋯ Chemotherapy with gemcitabine is the optimum adjuvant treatment with a balanced benefit-toxicity ratio for resected biliary tract cancer. Chemoradiation was more likely to cause toxic effects.
-
Aliment. Pharmacol. Ther. · Oct 2014
Randomized Controlled Trial Multicenter StudyRandomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
Opioid-induced constipation (OIC) is a common adverse effect of opioid therapy. ⋯ In patients with noncancer pain and opioid-induced constipation, naloxegol 25 mg/day up to 52 weeks was generally safe and well tolerated.